Oligonucleotide Therapeutics and Delivery Conference 2021

Temas de la conferencia
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable".

Organizador profesional (PCO)
SMI Group Limited

https://go.evvnt.com/774501-0?pid=4832

Ms. Jinna Sidhu